Un nuevo tratamiento preventivo contra la malaria es bien aceptado por mujeres embarazadas con VIH
The Pregnant women with HIV Special son susceptible to the infectious by malaria. Sin, They cannot receive standard intermittent preventive treatment with sulfadoxin-pyimetamine (IPTP-SP) Due to possible interactions with cotrimoxazole, a prescribed drug to prevent opportunistic infections in person with HIV.
With the aim of evaluating safe and effective alternatives, a team from the Global Health Institute of Barcelona (ISGlobal), a center imported by the «La Caixa» Foundation, in collaboration with the Manhiça Health Research Center (SCISMA), led to Caborá, the ASE of the investigation. As part of the study, Acceptance was explored of an alternative preventive treatment based on the monthly administration of Dihydroartemisinin-piperaquina (DHA-PQ). The results were published in the magazine BMC Public Health.
«In addition to its clinical efficacy, the success of the DHA-PQ also depends on the adhesion of pregnant women to the treatment, influenced by the social and cultural context,» explanation, explanation, explanation, Tacilta NhamposssaResearcher at the CISM and author of the study.
Trust in health professionals, key to acceptance
Medium Entresistas Made of pregnant women with and without HIV, as well as health professionals, the identifical study that All HIV positive women who participated in the essay accepted DHA-PQ Menuualment to unemployment. The main reason that motivated this acceptance was not so much the knowledge of the benefits of treatment, but the Great trust placed in health personnel.
Although some reported mild side effects, such as dizziness or nausea, participants I manifest his willingness to take DHA-PQ in future pregnanciesConvinced that he had contributed to a salary Emiazo.
The role of community entone
Both the women who participated in the essay and the health personnel indicated several factors that could increase the acceptance of the treatment: Access information About the benefits of DHA-PQ, The testimonies of other women Who had already received it, and the possibility of Receive medication at home.
«We must take advantage of the confidence placed in the health personnel to increase the understanding of the benefits of the DHA-PQ,» says Clara Menéndez, director of the maternal, infant and reproductive health initiative in Isglobal and study coordinator. «Training personal health health strategies and involving community agents is key to improving the coverage of these interventions and their acceptance within the community,» he concludes.
Reference
NHAMPOSSA, T., Torres, N., Chivangue, M.et al.Acceptability of dihydroartemisinin-piperaquina as an intermittent preventive treatment for pregnant women living with HIV in southern Mozambique.BMC Public Health25, 1633 (2025). https://doi.org/10.1186/s12889-025-22644-0
